467PPhase I trial of fruquintinib in patients with advanced solid tumors: Results of the dose escalation phase

ConclusionsFruquintinib is generally well-tolerated in heavily pretreated patients, with the safety profile consistent with that of other anti-angiogenic tyrosine kinase inhibitors. The RP2D in US pts is 5  mg qd (3/1), which is also the approved dose in China. Preliminary anticancer activity was evident in these pts with advanced solid tumors. The dose expansion phase of the study is ongoing. Further investigation of fruquintinib in pts with mCRC is planned.1 JAMA 2018; 319:2486.Clinical trial identificationNCT03251378.Editorial acknowledgementHoang-Lan Nguyen, PhD, Hutchison MediPharma (US), Inc.Legal entity responsible for the studyHutchison MediPharma, Limited.FundingHutchison MediPharma, Limited.DisclosureA. Wang-Gillam: Advisory / Consultancy: Tyme; Advisory / Consultancy: Merrimack; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Bristol-Myer Squibb; Advisory / Consultancy: Jacobio. H. Park: Research grant / Funding (institution): Ambrx; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Array Biopharma; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Daichi Pharmaceutical; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): EMD Serono; Research grant / Fu...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research